Status:
COMPLETED
Oral Anticoagulation in Hemodialysis
Lead Sponsor:
Onze Lieve Vrouw Hospital
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysi...
Detailed Description
The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysi...
Eligibility Criteria
Inclusion
- inclusion in the trial with clinicaltrials.gov identifier NCT02610933
- signed informed consent for this extension trial
Exclusion
- none
Key Trial Info
Start Date :
May 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT03799822
Start Date
May 1 2017
End Date
October 1 2020
Last Update
November 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OLV Hospital
Aalst, Belgium, 9300